Loading...
REUN logo

Reunion Neuroscience Inc.NasdaqGS:REUN Stock Report

Market Cap US$12.5m
Share Price
n/a
1Y-73.0%
7D0.9%
1D-0.9%
Portfolio Value
​
View

Reunion Neuroscience Inc.

NasdaqGS:REUN Stock Report

Market Cap: US$12.5m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Reunion Neuroscience (REUN) Stock Overview

Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company, develops therapeutic solutions for mental health conditions in North America. More details

REUN fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Risk Analysis

Makes less than USD$1m in revenue (CA$0)

Highly volatile share price over the past 3 months

Has less than 1 year of cash runway

Does not have a meaningful market cap ($17M)


REUN Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW479,582 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
BL
BlackGoat
IN
Investingwilly
RO
RockeTeller
DA
davidlsander
479,582 investors already sharing narratives
View all narratives

Reunion Neuroscience Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Reunion Neuroscience
Historical stock prices
Current Share PriceCA$1.12
52 Week HighCA$7.62
52 Week LowCA$0.63
Beta4.21
1 Month Change0.90%
3 Month Change45.47%
1 Year Change-72.96%
3 Year Changen/a
5 Year Changen/a
Change since IPO-89.05%

Recent News & Updates

Recent updates

Seeking Alpha • Oct 07

Reunion Neuroscience announces resignation of director, general counsel

Reunion Neuroscience (NASDAQ:REUN) on Friday announced the resignations of director Ronan Levy and general counsel & corporate secretary Paula Amy Hewitt. The company appointed CEO Greg Mayes to replace Levy as director. CFO Donna Wong as appointed as corporate secretary in place of Hewitt. REUN stock +4.9% to $1.94 after hours.
Seeking Alpha • Sep 28

Reunion Neuroscience appoints Greg Mayes as President and CEO

Reunion Neuroscience (NASDAQ:REUN) appoints Greg Mayes as President and Chief Executive Officer. Most recently he served as the President and CEO of Antios Therapeutics. It is anticipated that Mr. Mayes will be appointed to the Reunion Board of Directors to replace Ronan Levy, Reunion co-founder and current Chairman and CEO of Field Trip Health & Wellness Ltd., who will step down from Reunion’s Board in October 2022.
Seeking Alpha • Aug 15

Field Trip Health  GAAP EPS of -C$0.09

Field Trip Health  press release (NASDAQ:FTRP): Q1 GAAP EPS of -C$0.09. As of June 30, 2022, the Company had unrestricted cash, cash equivalents and short-term investments of C$52.3 million, including C$4.1 million held at the Clinic Operations. Shares +4.42% AH.
Seeking Alpha • Jun 29

Field Trip Health receives final court approval for clinics business spin-out

Psychedelic therapies company Field Trip Health (NASDAQ:FTRP) said it has received final court approval for the spin-out of its clinics business to Field Trip Health & Wellness. The spin-out is to be executed by way of a plan of arrangement, with the closing subject to regulatory approvals. As part of the arrangement, each share of FTRP will be exchanged for one common share of FTRP, to be renamed Reunion Neuroscience on consummation of the arrangement, and ~0.86 common share of Field Trip Health & Wellness. The closing of the arrangement is set to occur on or around August. Field Trip Health & Wellness will list on the TSX Venture Exchange, subject to the exchange's approval. Additionally, Field Trip Health closed a private placement of subscription receipts of Field Trip Health & Wellness. The private placement, led by Bloom Burton Securities, involved an issue price of C$0.50 per receipt, with aggregate gross proceeds of C$2.1M. The net proceeds of the offering will be used for clinic operating expenses, working capital, arrangement expenses as well as for general corporate purposes. Source: Press Release

Shareholder Returns

REUNUS BiotechsUS Market
7D0.9%-1.4%-1.4%
1Y-73.0%28.1%16.4%

Return vs Industry: REUN underperformed the US Biotechs industry which returned -4.2% over the past year.

Return vs Market: REUN underperformed the US Market which returned 14.1% over the past year.

Price Volatility

Is REUN's price volatile compared to industry and market?
REUN volatility
REUN Average Weekly Movement17.1%
Biotechs Industry Average Movement10.2%
Market Average Movement7.1%
10% most volatile stocks in US Market16.3%
10% least volatile stocks in US Market3.2%

Stable Share Price: REUN's share price has been volatile over the past 3 months.

Volatility Over Time: REUN's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
200816Greg Mayesreunionneuro.com

Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company, develops therapeutic solutions for mental health conditions in North America. The company’s lead asset includes RE104, a clinical-stage serotonergic psychedelic therapeutic product for antidepressant applications. It is also developing the RE200 series, which comprises molecules that are structurally designed to be similar to classical psychedelics with selective potency at the target serotonin 2A receptor (5HT2A) for potential chronic treatment in various patient populations and indications.

Reunion Neuroscience Inc. Fundamentals Summary

How do Reunion Neuroscience's earnings and revenue compare to its market cap?
REUN fundamental statistics
Market capUS$12.47m
Earnings (TTM)-US$28.55m
Revenue (TTM)n/a
0.0x
P/S Ratio
-0.4x
P/E Ratio

Is REUN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
REUN income statement (TTM)
RevenueCA$0
Cost of RevenueCA$0
Gross ProfitCA$0
Other ExpensesCA$38.10m
Earnings-CA$38.10m

Last Reported Earnings

Mar 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-3.25
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did REUN perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/08/03 23:08
End of Day Share Price 2023/07/31 00:00
Earnings2023/03/31
Annual Earnings2023/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Reunion Neuroscience Inc. is covered by 7 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David MartinBloom Burton & Co.
Elemer PirosD. Boral Capital LLC.
Patrick TrucchioH.C. Wainwright & Co.